Cutaneous Side Effects of Single Versus Combined BRAF Inhibitors: A Comment to Erfan et al.

Cutaneous Side Effects of Single Versus Combined BRAF Inhibitors: A Comment to Erfan et al.

Bibliographic Details
Main Authors:	Rachel Anforth, Pablo Fernandez-Penas
Format:	Article
Language:	English
Published:	Society for Publication of Acta Dermato-Venereologica 2017-09-01
Series:	Acta Dermato-Venereologica
Online Access:	https://www.medicaljournals.se/acta/content/html/10.2340/00015555-2763

Similar Items

erfan va namaz
by: muhammad nasiri
Published: (2020-04-01)

Cutaneous Side Effects of BRAF Inhibitors in Advanced Melanoma: Review of the Literature
by: Bilgen Gençler, et al.
Published: (2016-01-01)

Cutaneous wound healing through paradoxical MAPK activation by BRAF inhibitors
by: Helena Escuin-Ordinas, et al.
Published: (2016-08-01)

Prognostic role of BRAF in human cutaneous melanoma : gene versus protein expression
by: Safaee Ardekani, Gholamreza
Published: (2015)

The potential for BRAF V600 inhibitors in advanced cutaneous melanoma: rationale and latest evidence
by: Charlotte Lemech, et al.
Published: (2012-03-01)

Targeted Therapy for Cutaneous Melanoma: Beyond BRAF...
by: Michael A. Davies
Published: (2014-01-01)

BRAF/MEK inhibitor-induced remission of primary cutaneous myoepithelial carcinoma after local recurrence
by: Jacqueline Guidry, MD, et al.
Published: (2020-08-01)

Safety and Tolerability of BRAF Inhibitor and BRAF Inhibitor-Based Combination Therapy in Chinese Patients With Advanced Melanoma: A Real World Study
by: Xing Liu, et al.
Published: (2021-04-01)

Efficacy, Safety, and Tolerability of Approved Combination BRAF and MEK Inhibitor Regimens for <i>BRAF</i>-Mutant Melanoma
by: Omid Hamid, et al.
Published: (2019-10-01)

Intermittent Versus Continuous Dosing of MAPK Inhibitors in the Treatment of BRAF-Mutated Melanoma
by: Coralie Reger de Moura, et al.
Published: (2020-02-01)

Safety of BRAF+MEK Inhibitor Combinations: Severe Adverse Event Evaluation
by: Tomer Meirson, et al.
Published: (2020-06-01)

Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management
by: Jan Leipe, et al.
Published: (2019-06-01)

The combination of mutations in BRAF and NRAS genes within a one tumor in patients with cutaneous melanoma
by: M. B. Aksenenko, et al.
Published: (2019-10-01)

Clinico-economic analysis of PD-1 inhibitors and combinations of BRAF and MEK inhibitors for the treatment of metastatic melanoma with a BRAF V600 gene mutation
by: D. Yu. Belousov, et al.
Published: (2018-07-01)

The Role of Human Papillomaviruses and Polyomaviruses in BRAF-Inhibitor Induced Cutaneous Squamous Cell Carcinoma and Benign Squamoproliferative Lesions
by: Karin J. Purdie, et al.
Published: (2018-08-01)

Electrochemotherapy with bleomycin is effective in BRAF mutated melanoma cells and interacts with BRAF inhibitors
by: Dolinsek Tanja, et al.
Published: (2016-09-01)

Cardiovascular adverse events associated with BRAF versus BRAF/MEK inhibitor: Cross‐sectional and longitudinal analysis using two large national registries
by: Avirup Guha, et al.
Published: (2021-06-01)

Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy
by: Zeynep Eroglu, et al.
Published: (2016-01-01)

Prevalence of BRAF and NRAS mutations in cutaneous melanoma patients in Taiwan
by: Yi-Shuan Sheen, et al.
Published: (2016-02-01)

BRAF mutant colorectal cancer: ErbB2 expression levels as predictive factor for the response to combined BRAF/ErbB inhibitors
by: Evelina Miele, et al.
Published: (2020-02-01)

Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma
by: Ahmed, T., et al.
Published: (2022)

BRAF inhibitors and radiotherapy for melanoma brain metastases: potential advantages and disadvantages of combination therapy
by: Chowdhary M, et al.
Published: (2016-12-01)

Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
by: Muna Al Hashmi, et al.
Published: (2020-05-01)

Concurrent MEK2 Mutation and BRAF Amplification Confer Resistance to BRAF and MEK Inhibitors in Melanoma
by: Jessie Villanueva, et al.
Published: (2013-09-01)

Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered BRAF transcript splicing
by: Gulietta M. Pupo, et al.
Published: (2017-05-01)

BRAF mutation and its inhibitors in sarcoma treatment
by: Haotian Liu, et al.
Published: (2020-07-01)

BRAF Inhibitors: Molecular Targeting and Immunomodulatory Actions
by: Ilaria Proietti, et al.
Published: (2020-07-01)

Inhibitors of BRAF dimers using an allosteric site
by: Xiomaris M. Cotto-Rios, et al.
Published: (2020-09-01)

Inhibitors of pan PI3K signaling synergize with BRAF or MEK inhibitors to prevent BRAF-mutant melanoma cell growth
by: Melanie eSweetlove, et al.
Published: (2015-06-01)

Correlation of histopathological patterns in cutaneous melanoma with BRAF mutations Correlação de padrões histopatológicos de melanomas cutâneos com mutações BRAF
by: Juliana Elizabeth Jung, et al.
Published: (2010-12-01)

REPEATED USE OF BRAF AND MEK INHIBITORS IN METASTATIC MELANOMA PATIENTS AFTER PROFRESSION ON BRAF AND МЕК INHIBITORS. LITERATURE REVIEW AND CLINICAL OBSERVATION
by: I. V. Samoylenko, et al.
Published: (2017-11-01)

BRAF Inhibitors for BRAF V600E Mutant Colorectal Cancers: Literature Survey and Case Report
by: Yasar Subutay Peker, et al.
Published: (2018-01-01)

A Case Report: Cutaneous Metastasis of Advanced Rectal Cancer with BRAF Mutation
by: Zhou S, et al.
Published: (2021-02-01)

Arthralgia Induced by BRAF Inhibitor Therapy in Melanoma Patients
by: Martin Salzmann, et al.
Published: (2020-10-01)

Clinical Implications of Acquired BRAF Inhibitors Resistance in Melanoma
by: Paola Savoia, et al.
Published: (2020-12-01)

Adaptive Responses as Mechanisms of Resistance to BRAF Inhibitors in Melanoma
by: Azad Saei, et al.
Published: (2019-08-01)

BRAF V600E Inhibitor (Vemurafenib) for BRAF V600E Mutated Low Grade Gliomas
by: Francesca Del Bufalo, et al.
Published: (2018-11-01)

Efficacy of BRAF Inhibitors in Asian Metastatic Melanoma Patients: Potential Implications of Genomic Sequencing in BRAF-Mutated Melanoma
by: Hee Kyung Kim, et al.
Published: (2016-12-01)

Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models
by: Anais Del Curatolo, et al.
Published: (2018-07-01)

Deregulated FASN Expression in BRAF Inhibitor-Resistant Melanoma Cells Unveils New Targets for Drug Combinations
by: Serena Stamatakos, et al.
Published: (2021-05-01)